TGTX

TG Therapeutics, Inc. (TGTX) 2025 Annual Report Summary

Business Context and Reporting Period

This summary covers the Annual Report on Form 10-K for TG Therapeutics, Inc. for the fiscal year ended December 31, 2025. TG Therapeutics is a commercial-stage biotechnology company focused on B-cell mediated diseases. Its primary commercial product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the FDA in December 2022 for the treatment of relapsing forms of multiple sclerosis (RMS). The company launched BRIUMVI commercially in the U.S. in January 2023 and partnered with Neuraxpharm for ex-U.S. commercialization, which began in February 2024.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: Net income for 2025 includes a significant non-cash income tax benefit of $339.8 million resulting from the release of a deferred tax asset valuation allowance.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 87% year-over-year, driven primarily by a 93% increase in net product revenue from BRIUMVI ($606.9M vs. $313.7M). U.S. sales grew to $594.1 million, while sales to the ex-U.S. partner Neuraxpharm increased to $12.8 million.
• Profitability: The company achieved a substantial increase in net income ($447.2M vs. $23.4M). This was largely due to the release of the valuation allowance on deferred tax assets, rather than a proportional increase in operating cash flow.
• Expense Increases: Total costs and expenses rose to $493.0 million from $287.1 million.
  • R&D Expenses: Increased to $160.2 million (from $94.3 million), driven by subcutaneous ublituximab development and clinical trial costs.
  • SG&A Expenses: Increased to $232.0 million (from $154.3 million), reflecting expanded commercialization efforts and marketing spend.
  • Stock-Based Compensation: Total non-cash compensation expense rose to $64.7 million (from $42.5 million).
• Share Repurchases: The company completed its prior $100 million share repurchase program in September 2025, repurchasing 3.5 million shares at an average price of $28.55. A new $100 million repurchase program was authorized in September 2025, with no repurchases made under it by year-end.

Guidance, Outlook, and Risks

Outlook and Pipeline:

• Subcutaneous Ublituximab: Enrollment in the Phase 3 pivotal program is >75% complete. The trial compares subcutaneous regimens to IV BRIUMVI.
• ENHANCE Trial: Enrollment completed for the Phase 3b trial evaluating a consolidated dosing schedule for IV BRIUMVI.
• Azer-cel: First patient dosed in a Phase 1 trial for progressive multiple sclerosis in August 2025.
• Liquidity: Management anticipates existing cash, investments, and projected revenues will fund operations for more than 12 months.

Key Risks and Contingencies:

• Manufacturing Deviation: A $6.2 million inventory reserve was recorded in Q4 2025 due to a potential manufacturing deviation affecting one batch of bulk drug substance.
• Debt Covenants: The company has a $250 million term loan with Blue Owl Capital maturing in 2029. While currently in compliance, the loan is secured by substantially all assets and includes restrictive covenants.
• Regulatory & Commercialization: Risks include the ability to maintain regulatory approval for BRIUMVI, achieve market acceptance, and manage pricing/reimbursement pressures (e.g., Inflation Reduction Act).
• Third-Party Dependence: The company relies entirely on third-party contract manufacturers (Samsung Biologics, FUJIFILM Diosynth) and commercial partners (Neuraxpharm).

Investor Verification Checklist

• Tax Benefit Sustainability: Verify the assumptions behind the $339.8 million deferred tax asset release and the company's ability to sustain profitability to realize these assets in future periods.
• Inventory Reserve Impact: Assess the resolution of the manufacturing deviation that triggered the $6.2 million inventory reserve and its potential impact on future supply.
• Debt Service Capacity: Review the Total Net Leverage Ratio covenant thresholds and the company's ability to meet future interest and principal payments (amortization begins in 2028) without refinancing.
• Subcutaneous Trial Data: Monitor upcoming data readouts from the Phase 3 subcutaneous ublituximab trial, which is critical for expanding the patient base and competitive positioning.
• Neuraxpharm Performance: Evaluate the commercial performance of BRIUMVI in the EU and other ex-U.S. territories managed by Neuraxpharm, as this impacts royalty revenue and milestone payments.